Author

Hiromitsu Shibayama

Shionogi (Japan)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Akihiro Hori· 1 shared Haruaki NoboriiD· 1 shared Hirofumi SawaiD· 1 shared Jun SatoiD· 1 shared Kana Kurahashi· 1 shared Keiichiro Hirai· 1 shared Kenji NakaharaiD· 1 shared Masayuki TakamatsuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Akihiro Hori

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19

Yuto Unoh, Keiichiro Hirai, Shota Uehara, Sho Kawashima, Haruaki Nobori, Jun Sato, Hiromitsu Shibayama, Akihiro Hori, Kenji Nakahara, Kana Kurahashi, Masayuki Takamatsu, Shiho Yamamoto, Qianhui Zhang, Miki Tanimura, Reiko Dodo, , Yuki Tachibana

This paper describes the discovery of S-892216, a potent SARS-CoV-2 3CLpro inhibitor with antiviral activity against multiple variants and low cross-resistance to existing drugs.

Journal of Medicinal Chemistry · Jul 5, 2025Peer-reviewedBiochemistry